uniQure N.V. (QURE) Stock Ratings


View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:


Bullish

88% of 8 ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks
Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
Netteligent Netteligent 06/22/2015 3 months $33.25 $26.24 -21.08% 21 Active
Comments:
DrMedicalValue DrMedicalValue 05/24/2015 1 Year $26.43 $26.24 -0.72% -1 Active
Comments: Disruptive validated tech platform that does not reduce symptoms but QURES!
laurvp laurvp 05/12/2015 1 week $28.21 $27.67 -1.91% 1 Ended
Comments:
goedbegingoedbegin goedbegingoedbegin 04/14/2015 1 Year $29.76 $26.24 -11.83% -11 Active
Comments: undervalued
ashu210890 ashu210890 04/08/2015 1 month $33.16 $27.56 -16.89% -16 Ended
Comments:
Work Smarter Not Harder Work Smarter Not Harder 03/20/2015 1 Year $27.55 $26.24 -4.75% -4 Active
Comments: Price for a treatment, company is undervalued
MLL MLL 02/12/2015 1 Year $19.49 $26.24 +34.63% 34 Active
Comments: undervalued
just profit just profit 01/15/2015 1 Year $20.32 $26.24 +29.13% 29 Active
Comments: First gene therapy drug Glybera on the market by UniQure!

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.